^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:HER2 Positive Breast Cancer
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) +
    Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

    Excerpt:
    ...Recurrent or metastatic HER2-positive breast cancer (HER2 positive is defined per ASCO-CAP guidelines) 5....
    Trial ID:
    NCT03530696
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

    Excerpt:
    ...All subjects must have recurrent or metastatic HER2-positive breast cancer....
    Trial ID:
    NCT01976169
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Breast Cancer
    Title:

    A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy

    Published date:
    03/11/2021
    Excerpt:
    The combination of day 1 T-DM1 and days 5 to 18 palbociclib is safe, tolerable, and active in previously treated HER2-positive relapsed patients. Observed hematologic toxicity is manageable. The trial response rate confirms that a CDK 4/6 inhibitor can resensitize HER2-resistant breast cancer.
    DOI:
    10.1016/j.clbc.2021.03.005
    Trial ID:
    NCT01976169